PSTV - Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense | Benzinga
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs.
The award is expected to commence in Q3 2024 and will support the planned expansion of the company's clinical trial for pediatric brain cancer.
"This recent award further extends our current cash runway in the second half of 2025 while supporting the 2024 expansion of our clinical development activities," said Marc Hedrick, President & CEO of Plus Therapeutics.
"In 2023, the company applied ...